"Sales in Q3 2025 amounted to USD 237 million, representing 11% reported growth, of which 7% was organic.

Growth picked up in the third quarter as expected, driven by double-digit growth in Prosthetics & Neuro Orthotics. The solid momentum in EMEA continues and growth in Americas was strong following a soft start to the year, supported by our recently launched innovations.

The EBITDA margin was strong at 22% in Q3 2025 and 21% for the first nine months of the year compared to 20% (before special items) in the comparable period. In line with our performance recorded in the first nine months of 2025, our guidance for the full-year 2025 has been reiterated"